Anna V. Tinker

14.9k total citations · 2 hit papers
128 papers, 4.1k citations indexed

About

Anna V. Tinker is a scholar working on Reproductive Medicine, Oncology and Cancer Research. According to data from OpenAlex, Anna V. Tinker has authored 128 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Reproductive Medicine, 55 papers in Oncology and 31 papers in Cancer Research. Recurrent topics in Anna V. Tinker's work include Ovarian cancer diagnosis and treatment (68 papers), PARP inhibition in cancer therapy (30 papers) and Cancer Genomics and Diagnostics (28 papers). Anna V. Tinker is often cited by papers focused on Ovarian cancer diagnosis and treatment (68 papers), PARP inhibition in cancer therapy (30 papers) and Cancer Genomics and Diagnostics (28 papers). Anna V. Tinker collaborates with scholars based in Canada, United States and United Kingdom. Anna V. Tinker's co-authors include Michael Friedländer, Alison Davis, David D.L. Bowtell, Bianca Locandro, Joshy George, Anna DeFazio, Richard W. Tothill, Sián Fereday, Nadia Traficante and Daryl Johnson and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Anna V. Tinker

119 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

2008 1.0k citations Richard W. Tothill, Anna V. Tinker et al. Clinical Cancer Research profile →
Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer

2020 237 citations Ana Oaknin, Anna V. Tinker et al. profile →

Peers

Anna V. Tinker

ONCOL

Kathleen M. Darcy United States

Kenneth D. Swenerton Canada

David N. Church United Kingdom

Ingunn M. Stefansson Norway

Sián Fereday Australia

Werner Meier Germany

Helen Mackay Canada

Alexandra Léary France

Agustin A. García United States

Lars Hanker Germany

Kathleen M. Darcy United States

Anna V. Tinker

1.9k ×1.0

1.8k ×1.1

ONCOL

2.1k ×1.5

1.3k ×1.5

961 ×1.2

Citations per year, relative to Anna V. Tinker Anna V. Tinker (= 1×) peers Kathleen M. Darcy

Countries citing papers authored by Anna V. Tinker

Since Specialization

Citations

This map shows the geographic impact of Anna V. Tinker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna V. Tinker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna V. Tinker more than expected).

Fields of papers citing papers by Anna V. Tinker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna V. Tinker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna V. Tinker. The network helps show where Anna V. Tinker may publish in the future.

Co-authorship network of co-authors of Anna V. Tinker

This figure shows the co-authorship network connecting the top 25 collaborators of Anna V. Tinker. A scholar is included among the top collaborators of Anna V. Tinker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna V. Tinker. Anna V. Tinker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fernández, Marta Llauradó, Linda S. Cook, Stéphanie Gaillard, et al.. (2025). FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma. Journal of Gynecologic Oncology. 36(5). e74–e74. 3 indexed citations

Friedman, Claire F., Anishka D'souza, Diana Bello Roufai, et al.. (2024). Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial. Gynecologic Oncology. 181. 162–169. 15 indexed citations

Scott, Clare L., et al.. (2023). Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer. Therapeutic Advances in Medical Oncology. 15. 2602380–2602380. 13 indexed citations

Bauer, Todd M., Kathleen N. Moore, Janet S. Rader, et al.. (2023). A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors. Targeted Oncology. 18(4). 517–530. 21 indexed citations

Oaknin, Ana, Lucy Gilbert, Anna V. Tinker, et al.. (2023). A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer. Future Oncology. 19(25). 1709–1714. 1 indexed citations

Davies, Janine M., et al.. (2023). Using chemotherapy response by KELIM score to predict response to first line maintenance PARP inhibitor therapy in non-BRCA mutant/homologous recombination deficiency (HRD) unknown high grade serous ovarian cancer (HGSOC).. Journal of Clinical Oncology. 41(16_suppl). e17547–e17547. 1 indexed citations

Tinker, Anna V., Renaud Sabatier, Adriano Gravina, et al.. (2022). 2022-RA-1198-ESGO Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab. International Journal of Gynecological Cancer. 32. A414–A414. 5 indexed citations

Kwon, Janice S., Anna V. Tinker, Jennifer L. Santos, et al.. (2022). Germline Testing and Somatic Tumor Testing forBRCA1/2Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?. JCO Precision Oncology. 6(6). e2200033–e2200033. 8 indexed citations

Parker, Jeremy, Richard A. Moore, Tracy Tucker, et al.. (2021). Use of Treatment-Focused Tumor Sequencing to Screen for Germline Cancer Predisposition. Journal of Molecular Diagnostics. 23(9). 1145–1158. 2 indexed citations

10.

Lam, Stéphanie, Samuel Leung, Anna V. Tinker, et al.. (2021). From biobank and data silos into a data commons: convergence to support translational medicine. Journal of Translational Medicine. 19(1). 493–493. 20 indexed citations

11.

Liao, John B., William R. Gwin, Renata R. Urban, et al.. (2021). Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates. Journal for ImmunoTherapy of Cancer. 9(9). e003122–e003122. 17 indexed citations

12.

Tinker, Anna V., Holger W. Hirte, Diane Provencher, et al.. (2019). Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221. Clinical Cancer Research. 25(20). 6052–6060. 70 indexed citations

13.

Nazeran, Tayyebeh M., Angela Cheng, Anthony N. Karnezis, Anna V. Tinker, & C. Blake Gilks. (2018). Bartholin Gland Carcinoma: Clinicopathologic Features, Including p16 Expression and Clinical Outcome. International Journal of Gynecological Pathology. 38(2). 189–195. 16 indexed citations

14.

Kumar, Arvind, et al.. (2018). Single-agent bevacizumab for the management of refractory malignant effusions in heavily pretreated patients with recurrent high-grade serous cancers of the ovary, fallopian tube or peritoneum: results from a single institution. European Journal of Gynaecological Oncology. 39(6). 877–880.

15.

Mirza, Mansoor Raza, Lucy Gilbert, Michel Fabbro, et al.. (2017). The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial. Annals of Oncology. 28. v331–v332. 8 indexed citations

16.

Grewal, Jasleen, Peter Eirew, Martin Jones, et al.. (2017). Detection and genomic characterization of a mammary-like adenocarcinoma. Molecular Case Studies. 3(6). a002170–a002170. 10 indexed citations

17.

Fabbro, Michel, Kathleen N. Moore, Anne Dørum, et al.. (2017). Safety and Efficacy of Niraparib in Elderly Patients (Pts) with Recurrent Ovarian Cancer (OC). Annals of Oncology. 28. v332–v332. 7 indexed citations

18.

Kwon, Janice S., et al.. (2013). Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers. Obstetrics and Gynecology. 121(1). 14–24. 110 indexed citations

19.

Anglesio, Michael S., Jeremy M. Arnold, Joshy George, et al.. (2008). Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors. Molecular Cancer Research. 6(11). 1678–1690. 91 indexed citations

20.

Tothill, Richard W., Anna V. Tinker, Joshy George, et al.. (2008). Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome. Clinical Cancer Research. 14(16). 5198–5208. 1041 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact